Bio-Techne
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Bio-Techne and other ETFs, options, and stocks.About TECH
Bio-Techne Corp. is a global life sciences company providing innovative tools and bioactive reagents for research and clinical diagnostic communities. Its products assist scientific investigations into biological processes and the nature and progress of specific diseases.
TECH Key Statistics
Stock Snapshot
As of today, Bio-Techne(TECH) shares are valued at $67.30. The company's market cap stands at 10.45B, with a P/E ratio of 129.90 and a dividend yield of 47.9%.
As of 2026-02-07, Bio-Techne(TECH) stock has fluctuated between $65.85 and $67.60. The current price stands at $67.30, placing the stock +2.2% above today's low and -0.4% off the high.
The Bio-Techne(TECH)'s current trading volume is 1.55M, compared to an average daily volume of 2.76M.
During the past year, Bio-Techne(TECH) stock moved between $46.01 at its lowest and $75.69 at its peak.
During the past year, Bio-Techne(TECH) stock moved between $46.01 at its lowest and $75.69 at its peak.
TECH News
Bio-Techne (TECH) is back in focus after its latest quarterly results delivered higher profit than analyst forecasts, supported by wider operating margins and n...
Patrick B Donnelly, an analyst from Citi, maintained the Buy rating on Bio-Techne. The associated price target is $80.00. Claim 50% Off TipRanks Premium Unlock...
Citi raised the firm’s price target on Bio-Techne (TECH) to $80 from $70 and keeps a Buy rating on the shares following quarterly results. The firm notes detail...
Analyst ratings
63%
of 19 ratingsMore TECH News
Image source: The Motley Fool. Wednesday, February 4, 2026 at 9:00 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer — Kim Kelderman Chief Financ...
The latest update is out from Bio-Techne ( (TECH) ). On February 4, 2026, Bio-Techne reported second-quarter fiscal 2026 results for the period ended December...
Reports Q2 revenue $295.88M, consensus $290.74M. “I am pleased with the Bio-Techne (TECH) team’s continued execution in a stabilizing operating environment,” sa...
...
In late January and early February 2026, Bio-Techne launched its Cultrex Synthetic Hydrogel, a fully defined synthetic extracellular matrix designed to improve...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.